Navy Awards Contract to Develop Biosensors for Blood Pathogens and Warfare Threats

(Nanowerk News) Fairway Medical Technologies, Inc. has received a $900,000, 3-year contract from the Department of the Navy to apply its optoacoustic technology to the real-time detection of blood borne pathogens and biological warfare agents under battlefield conditions. This grant is part of a larger, $3 million project led by Prof. Randolph Glickman, Principal Investigator from the University of Texas Health Science Center (UTHSC) at San Antonio.
The grant, entitled "Rapid identification of pathogenic agents in biological samples using pulsed laser optoacoustic spectroscopy with targeted nanoparticle contrast agents," will be carried out as a collaborative project between UTHSC, Fairway Medical Technologies and the Naval Health Research Center Detachment Directed Energy Bioeffects Laboratory at Brooks City-Base.
"This research is intended to develop a rugged battlefield instrument capable of detecting biological agents such as anthrax, plague, smallpox, and others with the speed, accuracy, sensitivity and reliability of analytical techniques and instruments found in the state-of-the-art laboratory today," said Dr. Glickman.
The optoacoustic biosensor tests samples of blood plasma or other liquids by using monoclonal antibodies (MAB) targeted to specific pathogens. "Elongated gold nanoparticles designed to strongly absorb near-infrared laser pulses can be conjugated to each type of MAB to create a specificity mechanism that will signal the presence of targeted pathogens," explained Dr. Alexander Oraevsky, VP of Research and Development at Fairway and an inventor of this nano-biosensor. "When the nanoparticles produce an acoustic response to laser pulses, the presence and concentration of the pathogens is established." Unique ultrawide-band transducers developed by Fairway for medical imaging and other analytical optoacoustic systems fit the signal acquisition needs of this application, he added.
"This is an important continuation of Fairway's current government and industry-sponsored research. When the R&D part of this project is over, Fairway will manufacture the devices for the Navy and other DoD customers," said Fairway president James Meador.
"Early front-line detection of biological threats using this kind of rugged battlefield system will provide critical information that can save Navy sailors and lives of other US military personnel, as well as support fast, well-informed command decision-making," commented Norman Barsalou, project co-investigator from the Navy Bioeffects lab. "We are proud that this collaboration between the UT Health Science Center San Antonio, the Naval Health Research Center Detachment at Brooks and Fairway Medical Technologies can move this important work ahead."
About Fairway
Privately held Fairway, which has more than doubled its manufacturing and research capacity in the past 24 months, develops and commercializes products based on proprietary or licensed technologies, and provides contract development and manufacturing services for outside clients. A portfolio company of BCM Technologies, the venture capital subsidiary of Baylor College of Medicine, Fairway has close relationships with most of the research institutions located in the Texas Medical Center, and has successfully orchestrated the design, development and manufacturing of scores of medical products, including FDA Class III (life supporting) devices.
Source: Fairway Medical Technologies (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: